Abstract
Psoriasis is a chronic inflammatory disorder of the skin and joints mediated by aberrant activity of Th1 and Th17 cells. It also has been shown to be associated with an increased risk of coronary artery disease and metabolic syndrome, highlighting the associated systemic inflammation. Despite the multitude of treatment options available, some cases are still refractory to the available agents, necessitating innovative combination therapies for management. Here we report the second case of plaque psoriasis and psoriatic arthritis treated successfully with a combination of apremilast and secukinumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
